Loomis, Sayles & Company
ACRS icon

Loomis, Sayles & Company’s Aclaris Therapeutics ACRS Stock Holding History

Loomis, Sayles & Company’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-527,228
Closed -$9.24M – 873
2018
Q1 		$9.24M Sell
527,228
-18,650
-3% -$395K 0.02% 444
2017
Q4 		$13.5M Sell
545,878
-4,998
-0.9% -$122K 0.03% 369
2017
Q3 		$14.2M Buy
550,876
+73,259
+15% +$1.96M 0.03% 354
2017
Q2 		$13M Buy
477,617
+77,654
+19% +$2.11M 0.03% 363
2017
Q1 		$11.9M Buy
+399,963
New +$11.5M 0.03% 386

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Loomis, Sayles & Company's ACRS Position: Q2 2018 in Review

Loomis, Sayles & Company sold out of Aclaris Therapeutics (ACRS) in Q2 2018, closing a stake of 527,228 shares — an estimated $9.24M sold.

Loomis, Sayles & Company first reported a position in ACRS in Q1 2017 and held it in 5 quarters. The position peaked at $14.2M in Q3 2017. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2018.

  • Loomis, Sayles & Company reported no remaining Aclaris Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Loomis, Sayles & Company sold 527,228 Aclaris Therapeutics shares in Q2 2018, an estimated $9.24M.
  • Loomis, Sayles & Company first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 5 quarters.
  • Loomis, Sayles & Company's Aclaris Therapeutics position peaked at $14.2M in Q3 2017.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2018.

Based on Loomis, Sayles & Company's 13F filing for Q2 2018, filed 14 Aug 2018.